Viemed Healthcare/$VMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viemed Healthcare
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
- Ticker
- $VMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,438
- Headquarters
- Lafayette, United States
- Website
- www.viemed.com
VMD Metrics
BasicAdvanced
$343M
23.70
$0.38
-
-
Price and volume
Market cap
$343M
52-week high
$12.61
52-week low
$6.05
Average daily volume
223K
Financial strength
Current ratio
1.253
Quick ratio
0.942
Long term debt to equity
0.048
Total debt to equity
0.061
Interest coverage (TTM)
24.56%
Profitability
EBITDA (TTM)
57.298
Gross margin (TTM)
57.41%
Net profit margin (TTM)
5.03%
Operating margin (TTM)
8.66%
Effective tax rate (TTM)
29.20%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
8.19%
Return on equity (TTM)
11.25%
Valuation
Price to earnings (TTM)
23.699
Price to revenue (TTM)
1.109
Price to book
2.28
Price to tangible book (TTM)
3.81
Price to free cash flow (TTM)
16.099
Free cash flow yield (TTM)
6.21%
Free cash flow per share (TTM)
0.56
Growth
Revenue change (TTM)
21.81%
Earnings per share change (TTM)
11.95%
3-year revenue growth (CAGR)
22.27%
3-year earnings per share growth (CAGR)
16.58%
What the Analysts think about VMD
Analyst ratings (Buy, Hold, Sell) for Viemed Healthcare stock.
Analyst projections of the future price of Viemed Healthcare stock.
Bulls say / Bears say
Revenue reached a record $80.7 million in Q3, up 12.2% year on year as existing businesses expanded; Viemed also raised the lower end of its 2026 revenue outlook. That points to growth beyond the contribution from its Lehan acquisition. (Nasdaq, The Motley Fool)
Sleep therapy is scaling quickly: PAP patients grew 37.5% year on year in Q3 and sleep resupply patients rose 22.1%. A larger resupply base can support repeat sales and broaden growth beyond ventilator rentals. (Nasdaq)
Early maternal-health markets are encouraging, and management plans to enter two additional states per quarter from Q4. This offers room to extend the Lehan business through Viemed’s existing payer and operating relationships. (The Motley Fool)
The company raised its revenue outlook floor but lowered the top of its 2026 adjusted EBITDA range from $68 million to $66 million. Faster sales growth is therefore not yet translating into a stronger profit outlook. (Nasdaq)
Regulatory and payer scrutiny could raise costs or threaten reimbursement: Viemed says audit activity has picked up, while an administrative appeal left a disputed $2.2 million Medicare overpayment claim outstanding. The company says it is continuing to challenge the claim. (The Motley Fool, SEC)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
VMD Financial Performance
Revenues and expenses
VMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
VMD News
AllArticlesVideos
Funds containing VMD
Fund name | Fund size | $VMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.